Skip header and navigation

Refine By

35343 records – page 1 of 3535.

A < 1.7 cM interval is responsible for Dmo1 obesity phenotypes in OLETF rats.

https://arctichealth.org/en/permalink/ahliterature47295
Source
Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):110-2
Publication Type
Article
Author
Takeshi K Watanabe
Shiro Okuno
Yuki Yamasaki
Toshihide Ono
Keiko Oga
Ayako Mizoguchi-Miyakita
Hideo Miyao
Mikio Suzuki
Hiroshi Momota
Yoshihiro Goto
Hiroichi Shinomiya
Haretsugu Hishigaki
Isamu Hayashi
Toshihiro Asai
Shigeyuki Wakitani
Toshihisa Takagi
Yusuke Nakamura
Akira Tanigami
Author Affiliation
Otsuka GEN Research Institute, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan. tkw_watanabe@research.otsuka.co.jp
Source
Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):110-2
Language
English
Publication Type
Article
Keywords
Animals
Animals, Congenic
Body Weight - genetics
Crosses, Genetic
Diabetes Mellitus - genetics
Female
Hyperglycemia - genetics
Hyperlipidemia - blood - genetics
Male
Obesity
Phenotype
Rats
Rats, Inbred BN
Rats, Inbred OLETF
Research Support, Non-U.S. Gov't
Abstract
1. Dmo1 (Diabetes Mellitus OLETF type I) is a major quantitative trait locus for dyslipidaemia, obesity and diabetes phenotypes of male Otsuka Long Evans Tokushima Fatty (OLETF) rats. 2. Our congenic lines, produced by transferring Dmo1 chromosomal segments from the non-diabetic Brown Norway (BN) rat into the OLETF strain, have confirmed the strong, wide-range therapeutic effects of Dmo1 on dyslipidaemia, obesity and diabetes in the fourth (BC4) and fifth (BC5) generations of congenic animals. Analysis of a relatively small number of BC5 rats (n = 71) suggested that the critical Dmo1 interval lies within a
PubMed ID
14756694 View in PubMed
Less detail

The -1C to T polymorphism in the annexin A5 gene is not associated with the risk of acute myocardial infarction or sudden cardiac death in middle-aged Finnish males.

https://arctichealth.org/en/permalink/ahliterature53135
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Publication Type
Article
Date
2005
Author
K S Kaikkonen
S. Kakko
M L Kortelainen
J M Tapanainen
M J Savolainen
Y. Antero Kesäniemi
H V Huikuri
E R Savolainen
Author Affiliation
Division of Cardiology, Department of Internal Medicine, University of Oulu, Finland.
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Date
2005
Language
English
Publication Type
Article
Keywords
5' Untranslated Regions - genetics
Adult
Aged
Annexin A5 - genetics
Death, Sudden, Cardiac - epidemiology - etiology
Finland - epidemiology
Genetic markers
Genetic Predisposition to Disease
Genetic Screening
Humans
Male
Middle Aged
Myocardial Infarction - epidemiology - genetics
Polymorphism, Genetic
Research Support, Non-U.S. Gov't
Risk factors
Abstract
OBJECTIVE: A common polymorphism (-1C to T) in the translation initiation sequence of annexin A5 (ANV) gene has recently been associated with a decreased risk of acute myocardial infarction (AMI). The aim of the present study was to analyze the association between the ANV genepolymorphism and the risk of AMI and ischemic sudden cardiac death (SCD) in middle-aged Finnish males. MATERIAL AND METHODS: A case-control study involving three distinct groups of subjects was carried out: (1) victims of SCD (n=98), (2) survivors of AMI (n=212), and (3) randomly selected control subjects without any history of coronary heart disease (n=243). The ANV polymorphism was genotyped in each study group. RESULTS: Among the control group of healthy Finnish males the prevalence rates of the CC, CT, and TT genotypes were 83.1%, 15.2%, and 1.6%, respectively. Among the survivors of AMI, the prevalence rates of CC, CT, and TT were 79.7%, 20.3%, and 0%, respectively, and among the victims of SCD 83.7%, 16.3%, and 0%, respectively. No significant differences in the genotype or allele distributions were observed between the study groups. CONCLUSION: The -1C to T polymorphism in the ANV gene is not associated with the risk of AMI or SCD in middle-aged Finnish males.
PubMed ID
16025836 View in PubMed
Less detail

A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients.

https://arctichealth.org/en/permalink/ahliterature11215
Source
Chest. 1996 Jul;110(1):53-7
Publication Type
Article
Date
Jul-1996
Author
R A Pauwels
F E Hargreave
P. Camus
M. Bukoski
E. Ståhl
Author Affiliation
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
Source
Chest. 1996 Jul;110(1):53-7
Date
Jul-1996
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adrenergic beta-Agonists - administration & dosage
Adult
Asthma - drug therapy - physiopathology
Bronchodilator Agents - administration & dosage
Budesonide
Comparative Study
Female
Glucocorticoids - administration & dosage
Humans
Male
Nebulizers and Vaporizers
Peak Expiratory Flow Rate
Pregnenediones - administration & dosage
Research Support, Non-U.S. Gov't
Terbutaline - administration & dosage
Abstract
An open, randomized, parallel-group study was conducted to investigate whether asthmatic patients, considered adequately treated with a corticosteroid and/or short-acting beta 2-agonist via pressurized metered-dose inhaler (pMDI), could be transferred to a corresponding nominal dose of budesonide and/or terbutaline via Turbuhaler, an inspiratory flow-driven multidose dry powder inhaler (Astra Draco; Lund, Sweden), without a decrease in the effect of treatment. One thousand four patients (555 women; mean age, 44 years; mean peak expiratory flow [PEF], 102% predicted normal value) were randomized and treated with either pMDI (current therapy) or Turbuhaler for 52 weeks. The variables studied were asthma-related events, morning PEF, and inhaler-induced clinical symptoms. Asthma-related events were defined in two ways: (1) sum of health-care contacts plus doublings or additions of steroids, and (2) number of 2 consecutive days with PEF less than 80% of baseline. Baseline was obtained from a 2-week run-in period while receiving previous therapy. No statistically significant difference was found in asthma-related events according to definition 1. According to definition 2, there was a statistically significant difference between the groups in favor of Turbuhaler (p = 0.008). The mean number of events was 1.7 with Turbuhaler and 2.2 with pMDI. The mean number of weeks per patient with a PEF less than 90% of baseline was 4.5 with Turbuhaler compared with 6.0 with pMDI (p = 0.002). The sum of inhaler-induced symptoms after 1 year of use was statistically significantly lower with Turbuhaler (0.40) than with pMDI (0.75) (p = 0.0001). In conclusion, budesonide and terbutaline in Turbuhaler offered a superior alternative to corticosteroids and bronchodilators delivered by pMDIs in the maintenance treatment of asthma.
PubMed ID
8681664 View in PubMed
Less detail

A 1-year follow-up of low birth weight infants with and without bronchopulmonary dysplasia: health, growth, clinical lung disease, cardiovascular and neurological sequelae.

https://arctichealth.org/en/permalink/ahliterature59584
Source
Early Hum Dev. 1992 Sep;30(2):109-20
Publication Type
Article
Date
Sep-1992

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

2nd Scandinavian Breast Cancer Symposium. Bergen, Norway, May 23-24, 1985.

https://arctichealth.org/en/permalink/ahliterature26450
Source
Breast Cancer Res Treat. 1986;7 Suppl:S1-109
Publication Type
Article
Date
1986
Source
Breast Cancer Res Treat. 1986;7 Suppl:S1-109
Date
1986
Language
English
Publication Type
Article
Keywords
Aminoglutethimide - therapeutic use
Breast Neoplasms - drug therapy
Female
Humans
Research Support, Non-U.S. Gov't
PubMed ID
3742062 View in PubMed
Less detail

[2 new studies added on the status of children in society]

https://arctichealth.org/en/permalink/ahliterature43216
Source
Tidskr Sver Sjukskot. 1973 Oct 25;40(19):52-3
Publication Type
Article
Date
Oct-25-1973
Author
E. Monvall
Source
Tidskr Sver Sjukskot. 1973 Oct 25;40(19):52-3
Date
Oct-25-1973
Language
Swedish
Publication Type
Article
Keywords
Child Day Care Centers
Child Welfare
Research
Sweden
PubMed ID
4492002 View in PubMed
Less detail

2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.

https://arctichealth.org/en/permalink/ahliterature24099
Source
J Med Chem. 1993 Mar 19;36(6):765-70
Publication Type
Article
Date
Mar-19-1993
Author
S M Sami
R T Dorr
D S Alberts
W A Remers
Author Affiliation
Department of Pharmaceutical Sciences and Cancer Center, University of Arizona, Tucson 85721.
Source
J Med Chem. 1993 Mar 19;36(6):765-70
Date
Mar-19-1993
Language
English
Publication Type
Article
Keywords
Animals
Antineoplastic Agents - chemical synthesis - chemistry - therapeutic use
Female
Humans
Isoquinolines - chemical synthesis - chemistry - therapeutic use
Leukemia L1210 - drug therapy
Leukemia P388 - drug therapy
Male
Melanoma, Experimental - drug therapy
Mice
Mice, Inbred DBA
Ovarian Neoplasms - drug therapy
Research Support, U.S. Gov't, P.H.S.
Structure-Activity Relationship
Tumor Cells, Cultured - drug effects
Abstract
A new class of antitumor agents, having structural analogy to amonafide, but differing by the addition of a fourth ring in the nucleus, was synthesized conveniently from anthracene. Compounds with a variety of substituents, containing a basic nitrogen atom and located on the imide nitrogen, were prepared. Thirteen of 19 new compounds had greater growth inhibitory potency than amonafide in a panel of cultured murine and human tumor cells using the sulforhodamine B and MTT dye assays. The most active agents were similarly more toxic than amonafide to normal neonatal rat myocytes in vitro, but they had better chemotherapeutic indexes. From these compounds, the one with a 2-(dimethylamino)ethyl side chain (named azonafide) was chosen for further study. It showed high potency against a panel of cultured human colon cancer cells and it was active against ip P388 leukemia and subcutaneous B16 melanoma in mice. Preliminary structure-activity correlations suggest that the basicity of the side-chain nitrogen and the length of side chain are important determinants of antitumor potency in vitro. Steric hindrance and rigidity of the side chains might be other determinants.
PubMed ID
8459403 View in PubMed
Less detail

The 2-year course following detoxification treatment of substance abuse: the possible influence of psychiatric comorbidity.

https://arctichealth.org/en/permalink/ahliterature11106
Source
Eur Arch Psychiatry Clin Neurosci. 1997;247(6):320-7
Publication Type
Article
Date
1997
Author
K. Tómasson
P. Vaglum
Author Affiliation
Department of Psychiatry, National University Hospital, Landspítalinn, Reykjavík, Iceland.
Source
Eur Arch Psychiatry Clin Neurosci. 1997;247(6):320-7
Date
1997
Language
English
Publication Type
Article
Keywords
Adult
Alcoholism - psychology - rehabilitation
Diagnosis, Dual (Psychiatry) - psychology
Female
Follow-Up Studies
Humans
Male
Prospective Studies
Psychiatric Status Rating Scales
Research Support, Non-U.S. Gov't
Substance-Related Disorders - psychology - rehabilitation
Abstract
The influence of psychiatric comorbidity on the course and outcome in a nationwide representative sample (n = 351) of treatment-seeking substance users over a 28-month period was studied prospectively. The patients were administered the Diagnostic Interview Schedule and a questionnaire on drinking history. At 16 and 28 months after admission the patients returned a questionnaire on drinking history and mental health. In cases of those lacking information on either follow-up (45%), details on drinking status was obtained from informants. Completely abstinent were 16%. Generalized anxiety disorder and/or social phobia at the index admission predicted abstinence during the follow-up [odds ratio (OR) = 0.25], whereas onset of alcoholism among these patients after age 25 years predicted a worse prognosis (OR = 13.5). Also increasing number of social consequences related to abuse (OR = 1.3) and drinking more than the median (OR = 2.1) predicted a poor outcome. The abstinent group had significantly better mental health at follow-up. The patients with comorbid psychiatric disorders at admission were worse at follow-up. Although substance use disorders and comorbid psychiatric disorders have to a certain degree separate courses, there is nevertheless significant interaction between them. Early treatment and recognition of comorbid psychiatric disorders among substance abusers is necessary.
PubMed ID
9477012 View in PubMed
Less detail

3D visualization as a communicative aid in pharmaceutical advice-giving over distance.

https://arctichealth.org/en/permalink/ahliterature132831
Source
J Med Internet Res. 2011;13(3):e50
Publication Type
Article
Date
2011
Author
Ostlund M
Dahlbäck N
Petersson GI
Author Affiliation
eHealth Institute, Linnaeus University, Kalmar, Sweden. martin.ostlund@lnu.se
Source
J Med Internet Res. 2011;13(3):e50
Date
2011
Language
English
Publication Type
Article
Keywords
Adult
Diabetes Mellitus, Type 2 - drug therapy
Drug Interactions
Drug-Related Side Effects and Adverse Reactions
Female
Health Services Research
Humans
Imaging, Three-Dimensional - methods
Male
Middle Aged
Patient Education as Topic - methods
Pharmaceutical Services - utilization
Program Evaluation
Remote Consultation - methods
Sweden
Telemedicine - methods
Young Adult
Abstract
Medication misuse results in considerable problems for both patient and society. It is a complex problem with many contributing factors, including timely access to product information.
To investigate the value of 3-dimensional (3D) visualization paired with video conferencing as a tool for pharmaceutical advice over distance in terms of accessibility and ease of use for the advice seeker.
We created a Web-based communication service called AssistancePlus that allows an advisor to demonstrate the physical handling of a complex pharmaceutical product to an advice seeker with the aid of 3D visualization and audio/video conferencing. AssistancePlus was tested in 2 separate user studies performed in a usability lab, under realistic settings and emulating a real usage situation. In the first study, 10 pharmacy students were assisted by 2 advisors from the Swedish National Co-operation of Pharmacies' call centre on the use of an asthma inhaler. The student-advisor interview sessions were filmed on video to qualitatively explore their experience of giving and receiving advice with the aid of 3D visualization. In the second study, 3 advisors from the same call centre instructed 23 participants recruited from the general public on the use of 2 products: (1) an insulin injection pen, and (2) a growth hormone injection syringe. First, participants received advice on one product in an audio-recorded telephone call and for the other product in a video-recorded AssistancePlus session (product order balanced). In conjunction with the AssistancePlus session, participants answered a questionnaire regarding accessibility, perceived expressiveness, and general usefulness of 3D visualization for advice-giving over distance compared with the telephone and were given a short interview focusing on their experience of the 3D features.
In both studies, participants found the AssistancePlus service helpful in providing clear and exact instructions. In the second study, directly comparing AssistancePlus and the telephone, AssistancePlus was judged positively for ease of communication (P = .001), personal contact (P = .001), explanatory power (P
Notes
Cites: J Am Med Inform Assoc. 2003 May-Jun;10(3):260-7012626378
Cites: J Med Internet Res. 2009;11(2):e1719632971
Cites: Am J Health Syst Pharm. 1995 Feb 15;52(4):374-97757862
Cites: Int J Med Inform. 2005 Jan;74(1):21-3015626633
Cites: J Healthc Inf Manag. 2005 Spring;19(2):81-615869217
Cites: J Am Board Fam Pract. 2005 May-Jun;18(3):180-815879565
Cites: Cochrane Database Syst Rev. 2005;(4):CD00001116235271
Cites: Br J Gen Pract. 2005 Dec;55(521):956-6116378566
Cites: Ann Surg. 2006 Mar;243(3):291-30016495690
Cites: Int J Med Inform. 2006 Aug;75(8):565-7616298545
Cites: BMJ. 2007 May 5;334(7600):94217426062
Cites: Stud Health Technol Inform. 2007;129(Pt 1):82-617911683
Cites: Int J Med Inform. 2008 Feb;77(2):114-2117317292
Cites: J Behav Ther Exp Psychiatry. 2008 Sep;39(3):250-6117720136
Cites: J Med Internet Res. 2008;10(3):e2618762473
Cites: Eur J Clin Pharmacol. 1981;20(3):193-2007286037
PubMed ID
21771714 View in PubMed
Less detail

35343 records – page 1 of 3535.